- Home
- AMST vs NXTC Comparison
AMST vs NXTC Comparison
Compare AMST & NXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMST
- NXTC
- Stock Information
- Founded
- AMST 2017
- NXTC 2015
- Country
- AMST United States
- NXTC United States
- Employees
- AMST 11
- NXTC N/A
- Industry
- AMST Computer Software: Prepackaged Software
- NXTC Biotechnology: Pharmaceutical Preparations
- Sector
- AMST Technology
- NXTC Health Care
- Exchange
- AMST Nasdaq
- NXTC Nasdaq
- Market Cap
- AMST 15.7M
- NXTC 13.0M
- IPO Year
- AMST 2020
- NXTC 2019
- Fundamental
- Price
- AMST $3.14
- NXTC $5.78
- Analyst Decision
- AMST
- NXTC Strong Buy
- Analyst Count
- AMST 0
- NXTC 2
- Target Price
- AMST N/A
- NXTC $25.50
- AVG Volume (30 Days)
- AMST 2.1M
- NXTC 13.3K
- Earning Date
- AMST 11-13-2025
- NXTC 11-06-2025
- Dividend Yield
- AMST N/A
- NXTC N/A
- EPS Growth
- AMST N/A
- NXTC N/A
- EPS
- AMST N/A
- NXTC N/A
- Revenue
- AMST $82,544.00
- NXTC N/A
- Revenue This Year
- AMST N/A
- NXTC N/A
- Revenue Next Year
- AMST N/A
- NXTC N/A
- P/E Ratio
- AMST N/A
- NXTC N/A
- Revenue Growth
- AMST N/A
- NXTC N/A
- 52 Week Low
- AMST $2.00
- NXTC $2.69
- 52 Week High
- AMST $6.27
- NXTC $19.20
- Technical
- Relative Strength Index (RSI)
- AMST 53.57
- NXTC 65.09
- Support Level
- AMST $3.11
- NXTC $5.19
- Resistance Level
- AMST $3.56
- NXTC $5.90
- Average True Range (ATR)
- AMST 0.28
- NXTC 0.29
- MACD
- AMST 0.05
- NXTC 0.08
- Stochastic Oscillator
- AMST 24.77
- NXTC 89.38
About AMST Amesite Inc.
Amesite Inc is an artificial intelligence-driven platform and course designer that rapidly provides customized, high-performance and scalable online products for schools and businesses. The company helps educational institutions and businesses improve learning as their technology partner, delivering a disruptive technology driven by AI and offers a constellation of services that help partners implement new programs, and improve existing ones. Its customers are Enterprises, universities, and K-12 schools.
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.